LUMIERE on the PLACENTA

Overview

The frequency of IUGR is between 3 and 10% of births. The etiologies and mechanisms of IUGR are multiple. The placental insufficiency, that is the defect of perfusion, is, however, the principal mechanism, far in front of other maternal or fetal causes. This placental insufficiency is also now recognized as an essential risk factor for cardiovascular and metabolic diseases, such as diabetes, in adulthood. The interest in understanding in utero development is thus further increased by the short-, medium- and long-term consequences of placental dysfunction. However, there are few ways to evaluate uteroplacental vascularization in vivo. MRI is an imaging technique used routinely in the exploration of the fetus in addition to ultrasound. Its safety on the fetus and the mother is largely demonstrated at 1.5T. There are also MRI sequences used daily in the clinic to evaluate perfusion and organ structure in children and adults (brain, kidney, heart, etc.). Their application for evaluation of perfusion and placental structure, although still confined to research, is very promising. The investigator's team has extensive experience, in animals or in children, in the use of these sequences that could be used to evaluate placental function in vivo. The ASL (Arterial Spin Labeling) in particular is the most encouraging functional imaging technique because it allows today to measure an organ blood flow quantitatively and without injection of contrast medium.

Full Title of Study: “LUMIERE on the PLACENTA : A Study on the Added Value of MRI”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 2023

Detailed Description

The inclusion will take place at the earliest at 20 weeks after the completion of the standard morphological ultrasound of the 2nd trimester (carried out at 20-24SA) and at the latest at 35 SA, within the framework of one of the 2 clinical subgroups of patients considered (high risk and low risk). The objectives of this study will be achieved by the prospective setting up of a LUMIERE cohort on PLACENTA.

Interventions

  • Other: Fetal MRI
    • The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus(es)

Arms, Groups and Cohorts

  • Group 1: High risk IUGR patients
    • EPF<10th perc or PA<10th perc and Doppler ombilical IP> 95th percentile, EPF or PA<3th perc (reference curves from Collège Français d’Echographie Fœtale, between 20 et 34 GW),
  • Group 2: Low risk IUGR patients
    • EPF et PA>20th perc (reference curves from Collège Français d’Echographie Fœtale, between 20 et 34 GW)

Clinical Trial Outcome Measures

Primary Measures

  • Changes in placental blood flow as seen in vascular IUGR
    • Time Frame: From inclusion to end of neonatal period (max 25 weeks)
    • 25% reduction in overall placental perfusion measured ASL with IUGR (defined as <3th perc birth weight) versus controls (birth weight> 10th perc)

Secondary Measures

  • Placental response to maternal oxygenation (BOLD)
    • Time Frame: From inclusion to end of neonatal period (max 25 weeks)
    • BOLD effect
  • structural changes of the placenta
    • Time Frame: From inclusion to end of neonatal period (max 25 weeks)
    • Diffusion coefficient (ADC)
  • structural changes of the placenta
    • Time Frame: From inclusion to end of neonatal period (max 25 weeks)
    • T2 * mapping
  • Measurement of placental volume
    • Time Frame: From inclusion to end of neonatal period (max 25 weeks)
    • Placental segmentation
  • Measurement of IUGR by fetal segmentation (MRI),
    • Time Frame: From inclusion to end of neonatal period (max 25 weeks)
    • Fetal volume
  • evaluation of brain resonance
    • Time Frame: From inclusion to end of neonatal period (max 25 weeks)
    • BOLD effect, – ADC coefficient and IVIM parameters by variation of T2 * relaxation time
  • evaluation of kidney resonance
    • Time Frame: From inclusion to end of neonatal period (max 25 weeks)
    • BOLD effect, – ADC coefficient and IVIM parameters by variation of T2 * relaxation time
  • evaluation of liver resonance
    • Time Frame: From inclusion to end of neonatal period (max 25 weeks)
    • BOLD effect, – ADC coefficient and IVIM parameters by variation of T2 * relaxation time
  • Reproducibility of the examination analysis
    • Time Frame: After study completion, an average of one year
    • Correlations between microcirculatory parameters in utero, fetal weight at MRI and birth weight
  • Uterine arteries
    • Time Frame: From inclusion to end of neonatal period (max 25 weeks)
    • Measurement of blood flow in the uterine arteries by MRI 4D FLOW (in development) and Doppler (US) (feasibility study)
  • Acceptability of the examination for the patient: questionnaire
    • Time Frame: at IRM examination
    • Will be assessed by a questionnaire given to pregnant women after the MRI,
  • Acceptability of the examination for the patient: Likert scale
    • Time Frame: at IRM examination
    • will be assessed once by a Likert scale: 4 points Likert (poor, average, good, very good)
  • Specific Absorption Rate for each type of sequence
    • Time Frame: From inclusion to end of neonatal period (max 25 weeks)
    • SAR measurement (Specific Absorption Rate)

Participating in This Clinical Trial

Inclusion Criteria

  • Singleton pregnancy without fetal malformation seen on ultrasound. Group 1: High risk IUGR patients – EPF<10th perc or PA<10th perc and Doppler ombilical IP> 95th percentile, – EPF or PA<3th perc reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW, Group 2: Low risk IUGR patients • EPF et PA>20th perc reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW Exclusion Criteria:

  • – Contraindication to MRI – Impossible subsequent follow up – Maternal status contraindicates continuation of pregnancy – Participation in another search – "Protected" patient

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Assistance Publique – Hôpitaux de Paris
  • Collaborator
    • LUMIERE Fondation ( fondation-lumiere.org) under the aegis of Fondation de France
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Laurent Salomon, MD, PhD, Principal Investigator, Principal Investigator

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.